Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example

Journal of Clinical Oncology · Published 2026-08-05 · DOI 10.1200/jco-26-01002

Free full text

Authors (3)

Youngwoo Cho, Axel-R. Hanauske, Mark J. Ratain

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Cho, Y., Hanauske, A., Ratain, M. (2026). Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01002

Related articles

• Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · Journal of Clinical Oncology · 2026 · Same journal
• Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · Journal of Clinical Oncology · 2026 · Same journal
• Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · Journal of Clinical Oncology · 2026 · Same journal
• AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · Journal of Clinical Oncology · 2026 · Same journal
• Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · Journal of Clinical Oncology · 2026 · Same journal
• Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · Journal of Clinical Oncology · 2026 · Same journal
• SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · Journal of Clinical Oncology · 2026 · Same journal
• Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · Journal of Clinical Oncology · 2026 · Same journal
• Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · Journal of Clinical Oncology · 2026 · Same journal
• Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? · Journal of Clinical Oncology · 2026 · Same journal